We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NYT:NYSENew York Times Company (The) Analysis

Data as of 2026-04-21 - not real-time

$81.07

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The New York Times Company is trading at $81.07, comfortably above its 20‑day SMA of 82.51 and the 50‑day SMA of 79.65, while the 200‑day SMA sits at 66.05, indicating a bullish long‑term trend. Volume is increasing and the price is holding above the identified support level of $75.98, yet the MACD histogram is negative (‑0.57) and the signal line is bearish, suggesting short‑term momentum may be waning. The RSI of 50.2 points to a neutral stance, and the stock sits near the upper end of its 52‑week range ($87.10 resistance).
Fundamentally, NYT delivers strong revenue growth of 10.5% and healthy operating margins (20.8%), supported by a robust subscription base and diversified digital products. However, the forward‑looking DCF fair value of $62.10 is well below the current price, producing a downside of roughly 10%, and the PE ratio of 38.8× far exceeds the industry average of 19.1×, flagging potential overvaluation. The dividend yield of 1.15% with a payout ratio of 40.7% appears sustainable given ample cash flow and modest debt levels.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with bearish MACD
  • Increasing volume but neutral RSI
  • Support level at $75.98 provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 10.5% and strong operating margins
  • Sustainable dividend and low payout ratio
  • Bullish long‑term trend above 200‑day SMA

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Brand strength and expanding digital subscription ecosystem
  • Consistent cash generation and low leverage
  • Diversified product mix (news, sports, cooking, audio) reducing reliance on any single line

Key Metrics & Analysis

Financial Health

Revenue Growth10.50%
Profit Margin12.29%
P/E Ratio38.8
ROE17.33%
ROA9.43%
Debt/Equity2.39
P/B Ratio6.4
Op. Cash Flow$584.5M
Free Cash Flow$445.9M
Industry P/E19.1

Technical Analysis

TrendBullish
RSI50.2
Support$75.98
Resistance$87.10
MA 20$82.51
MA 50$79.65
MA 200$66.05
MACDBearish
VolumeIncreasing
Fear & Greed Index86.07

Valuation

Fair Value$62.10
Target Price$72.88
Upside/Downside-10.10%
GradeOvervalued
TypeGrowth
Dividend Yield1.15%

Risk Assessment

Beta0.30
Volatility27.33%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.